Skip to main content
. 2018 Oct 23;33(1):163–169. doi: 10.1111/jdv.15232

Figure 4.

Figure 4

Ongoing long‐term* or short‐term* prophylaxis for patients with available prophylaxis data. *At IOS entry and/or during the follow‐up period. **Zero count. Other countries include patients from Austria, Brazil, Denmark, France, Greece, Israel, Italy, Spain, Sweden and the United Kingdom.